COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP

The EHA-IDWP developed an observational registry collecting data on COVID-19 infection in patients who received CAR T-cell therapy. Prevalence of COVID-19 was 4.8%, and overall mortality was 50%, highlighting the need for prevention of infection in these patients.

Detalles Bibliográficos
Autores principales: Busca, Alessandro, Salmanton-García, Jon, Corradini, Paolo, Marchesi, Francesco, Cabirta, Alba, Di Blasi, Roberta, Dulery, Remy, Lamure, Sylvain, Farina, Francesca, Weinbergerová, Barbora, Batinić, Josip, Nordlander, Anna, López-García, Alberto, Drgoňa, Ľuboš, Espigado-Tocino, Ildefonso, Falces-Romero, Iker, García-Sanz, Ramón, García-Vidal, Carolina, Guidetti, Anna, Khanna, Nina, Kulasekararaj, Austin, Maertens, Johan, Hoenigl, Martin, Klimko, Nikolai, Koehler, Philipp, Pagliuca, Antonio, Passamonti, Francesco, Cornely, Oliver A., Pagano, Livio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Stimulus Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575532/
https://www.ncbi.nlm.nih.gov/pubmed/34749396
http://dx.doi.org/10.1182/bloodadvances.2021005616

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575532/
https://www.ncbi.nlm.nih.gov/pubmed/34749396
http://dx.doi.org/10.1182/bloodadvances.2021005616

Ejemplares similares